114 related articles for article (PubMed ID: 34908006)
1. Different Response to Immunotherapy According to Melanoma Histologic Subtype.
Pala L; Conforti F; Pagan E; Bagnardi V; De Pas TM; Mazzarol G; Barberis M; Pennacchioli E; Orsolini G; Prestianni P; Zagami P; Nicolo' E; Patanè D; Saponara M; Queirolo P
J Immunother; 2022 Feb-Mar 01; 45(2):119-124. PubMed ID: 34908006
[TBL] [Abstract][Full Text] [Related]
2. Major Histotypes in Skin Melanoma: Nodular and Acral Lentiginous Melanomas Are Poor Prognostic Factors for Relapse and Survival.
Tas F; Erturk K
Am J Dermatopathol; 2022 Nov; 44(11):799-805. PubMed ID: 35925149
[TBL] [Abstract][Full Text] [Related]
3. Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy.
Lattanzi M; Lee Y; Simpson D; Moran U; Darvishian F; Kim RH; Hernando E; Polsky D; Hanniford D; Shapiro R; Berman R; Pavlick AC; Wilson MA; Kirchhoff T; Weber JS; Zhong J; Osman I
J Natl Cancer Inst; 2019 Feb; 111(2):180-188. PubMed ID: 29912415
[TBL] [Abstract][Full Text] [Related]
4. Homologous recombination repair gene mutations as a predictive biomarker for immunotherapy in patients with advanced melanoma.
You Z; Lv M; He X; Pan Y; Ge J; Hu X; Zheng Y; Huang M; Zhou C; You C
Front Immunol; 2022; 13():871756. PubMed ID: 35990677
[TBL] [Abstract][Full Text] [Related]
5. Changes in the presentation of nodular and superficial spreading melanomas over 35 years.
Warycha MA; Christos PJ; Mazumdar M; Darvishian F; Shapiro RL; Berman RS; Pavlick AC; Kopf AW; Polsky D; Osman I
Cancer; 2008 Dec; 113(12):3341-8. PubMed ID: 18988292
[TBL] [Abstract][Full Text] [Related]
6. In vivo microscopic features of nodular melanomas: dermoscopy, confocal microscopy, and histopathologic correlates.
Segura S; Pellacani G; Puig S; Longo C; Bassoli S; Guitera P; Palou J; Menzies S; Seidenari S; Malvehy J
Arch Dermatol; 2008 Oct; 144(10):1311-20. PubMed ID: 18936395
[TBL] [Abstract][Full Text] [Related]
7. Comparative genomic hybridization analysis of hereditary swine cutaneous melanoma revealed loss of the swine 13q36-49 chromosomal region in the nodular melanoma subtype.
Apiou F; Vincent-Naulleau S; Spatz A; Vielh P; Geffrotin C; Frelat G; Dutrillaux B; Le Chalony C
Int J Cancer; 2004 Jun; 110(2):232-8. PubMed ID: 15069687
[TBL] [Abstract][Full Text] [Related]
8. Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study).
Nakamura Y; Namikawa K; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Fujimoto N; Kuwatsuka Y; Onishi M; Kaneko T; Onuma T; Umeda Y; Ogata D; Takahashi A; Otsuka M; Teramoto Y; Yamazaki N
ESMO Open; 2021 Dec; 6(6):100325. PubMed ID: 34839104
[TBL] [Abstract][Full Text] [Related]
9. Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials.
Zhou L; Wang X; Chi Z; Sheng X; Kong Y; Mao L; Lian B; Tang B; Yan X; Bai X; Li S; Guo J; Cui C; Si L
Front Immunol; 2021; 12():691032. PubMed ID: 34290710
[TBL] [Abstract][Full Text] [Related]
10. TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma.
Hodi FS; Wolchok JD; Schadendorf D; Larkin J; Long GV; Qian X; Saci A; Young TC; Srinivasan S; Chang H; Tang H; Wind-Rotolo M; Rizzo JI; Jackson DG; Ascierto PA
Cancer Immunol Res; 2021 Oct; 9(10):1202-1213. PubMed ID: 34389558
[TBL] [Abstract][Full Text] [Related]
11. Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients.
Nakamura Y; Namikawa K; Kiniwa Y; Kato H; Yamasaki O; Yoshikawa S; Maekawa T; Matsushita S; Takenouchi T; Inozume T; Nakai Y; Fukushima S; Saito S; Otsuka A; Fujimoto N; Isei T; Baba N; Matsuya T; Tanaka R; Kaneko T; Onishi M; Kuwatsuka Y; Nagase K; Onuma T; Nomura M; Umeda Y; Yamazaki N
Eur J Cancer; 2022 Nov; 176():78-87. PubMed ID: 36194906
[TBL] [Abstract][Full Text] [Related]
12. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
[TBL] [Abstract][Full Text] [Related]
13. Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment Registry.
Rauwerdink DJW; van Doorn R; van der Hage J; Van den Eertwegh AJM; Haanen JBAG; Aarts M; Berkmortel F; Blank CU; Boers-Sonderen MJ; De Groot JWB; Hospers GAP; de Meza M; Piersma D; Van Rijn RS; Stevense M; Van der Veldt A; Vreugdenhil G; Wouters MWJM; Suijkerbuijk K; van der Kooij M; Kapiteijn E
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428787
[TBL] [Abstract][Full Text] [Related]
14. Next-generation sequencing in advanced Chinese melanoma reveals therapeutic targets and prognostic biomarkers for immunotherapy.
Huang F; Li J; Wen X; Zhu B; Liu W; Wang J; Jiang H; Ding Y; Li D; Zhang X
Sci Rep; 2022 Jun; 12(1):9559. PubMed ID: 35688842
[TBL] [Abstract][Full Text] [Related]
15. Association of Histologic Regression With a Favorable Outcome in Patients With Stage 1 and Stage 2 Cutaneous Melanoma.
El Sharouni MA; Aivazian K; Witkamp AJ; Sigurdsson V; van Gils CH; Scolyer RA; Thompson JF; van Diest PJ; Lo SN
JAMA Dermatol; 2021 Feb; 157(2):166-173. PubMed ID: 33355600
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of adjuvant therapy for stage III BRAF-mut melanoma: A real-world retrospective study from single center in China.
Zhong J; Sun W; Hu T; Wang C; Yan W; Luo Z; Liu X; Xu Y; Chen Y
Cancer Med; 2023 May; 12(10):11475-11482. PubMed ID: 37016119
[TBL] [Abstract][Full Text] [Related]
17. Patterns of local horizontal spread of melanomas: consequences for surgery and histopathologic investigation.
Breuninger H; Schlagenhauff B; Stroebel W; Schaumburg-Lever G; Rassner G
Am J Surg Pathol; 1999 Dec; 23(12):1493-8. PubMed ID: 10584702
[TBL] [Abstract][Full Text] [Related]
18. Multivariate analysis of prognostic factors in patients with nodular melanoma.
Susok L; Stücker M; Bechara FG; Stockfleth E; Gambichler T
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2759-2764. PubMed ID: 33630139
[TBL] [Abstract][Full Text] [Related]
19. Analysis of clinical, dermoscopic and histopathological features of primary melanomas of patients with metastatic disease--a retrospective study at the Department of Dermatology, Medical University of Graz, 2000-2010.
Richtig G; Richtig E; Massone C; Hofmann-Wellenhof R
J Eur Acad Dermatol Venereol; 2014 Dec; 28(12):1776-81. PubMed ID: 24576192
[TBL] [Abstract][Full Text] [Related]
20. The Predictive Value of
Ye T; Zhang JY; Liu XY; Zhou YH; Yuan SY; Yang MM; Xie WZ; Gao C; Chen YX; Huang ML; Ye CZ; Chen J
Front Immunol; 2021; 12():785526. PubMed ID: 35069558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
